NCT02380924View on ClinicalTrials.gov

Recovery and Survival of EryDex in Non-patient Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Healthy
Interventions
DRUG

DSP loaded RBC using EryDex System

Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.

DRUG

Sham treated RBC using the EryDex System

Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.

Trial Locations (1)

03576

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Quince Therapeutics S.p.A.

INDUSTRY

NCT02380924 - Recovery and Survival of EryDex in Non-patient Volunteers | Biotech Hunter | Biotech Hunter